{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Virus+Shedding",
    "query": {
      "condition": "Virus Shedding"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 54,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Virus+Shedding&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T18:47:12.173Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00129818",
      "title": "A Study to Evaluate the Effect of Famciclovir in Reducing Herpes Virus Shedding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "name": "Famciclovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2004-07",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2012-04-27",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 7,
      "location_summary": "Birmingham, Alabama • Orlando, Florida • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00129818"
    },
    {
      "nct_id": "NCT05687279",
      "title": "Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Syncytial Virus Infection"
      ],
      "interventions": [
        {
          "name": "RSVt Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Control Group",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "6 Months to 23 Months"
      },
      "enrollment_count": 80,
      "start_date": "2023-02-06",
      "completion_date": "2024-12-27",
      "has_results": true,
      "last_update_posted_date": "2026-01-26",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 2,
      "location_summary": "Norfolk, Nebraska • Omaha, Nebraska",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Nebraska"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05687279"
    },
    {
      "nct_id": "NCT04529538",
      "title": "Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Poliomyelitis"
      ],
      "interventions": [
        {
          "name": "Novel Oral Polio Vaccine Type 1 (nOPV1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Novel Oral Polio Vaccine Type 3 (nOPV3)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "PATH",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 226,
      "start_date": "2021-03-26",
      "completion_date": "2023-02-17",
      "has_results": true,
      "last_update_posted_date": "2024-11-20",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 4,
      "location_summary": "Baltimore, Maryland • Lebanon, New Hampshire • Chapel Hill, North Carolina + 1 more",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04529538"
    },
    {
      "nct_id": "NCT00803543",
      "title": "Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Valacyclovir",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2009-01",
      "completion_date": "2014-04",
      "has_results": true,
      "last_update_posted_date": "2017-07-13",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00803543"
    },
    {
      "nct_id": "NCT01448616",
      "title": "Effect of Tenofovir on Genital Herpes Simplex Virus (HSV) Shedding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Simplex Type II"
      ],
      "interventions": [
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "Placebo Vaginal Gel",
          "type": "DRUG"
        },
        {
          "name": "Vaginal TFV Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo Tablets",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 73,
      "start_date": "2012-02",
      "completion_date": "2015-06",
      "has_results": true,
      "last_update_posted_date": "2023-02-16",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01448616"
    },
    {
      "nct_id": "NCT00686075",
      "title": "A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MEDI-534, Cohort 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 1",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 2",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 3",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 3",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 4",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 4",
          "type": "OTHER"
        },
        {
          "name": "MEDI-534, Cohort 5",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo, Cohort 5",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "MedImmune LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "23 Months",
        "sex": "ALL",
        "summary": "2 Months to 23 Months"
      },
      "enrollment_count": 1338,
      "start_date": "2008-06",
      "completion_date": "2012-08",
      "has_results": true,
      "last_update_posted_date": "2014-09-26",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 51,
      "location_summary": "Mobile, Alabama • Bentonville, Arkansas • Little Rock, Arkansas + 44 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Bentonville",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00686075"
    },
    {
      "nct_id": "NCT04478019",
      "title": "SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "COVID-19",
        "SARS-CoV 2"
      ],
      "interventions": [
        {
          "name": "10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Wisconsin, Madison",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 245,
      "start_date": "2020-07-07",
      "completion_date": "2022-06-30",
      "has_results": false,
      "last_update_posted_date": "2022-07-14",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04478019"
    },
    {
      "nct_id": "NCT00161434",
      "title": "A Study of Valacyclovir to Suppress HSV and HIV Shedding in Coinfected Persons",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Herpes Simplex",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "valacyclovir",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2003-03",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2008-01-10",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00161434"
    },
    {
      "nct_id": "NCT04911777",
      "title": "Proof of Principle Study to Evaluate the Safety, PK, Viral Shedding and Efficacy of Pentarlandir™ UPPTA for Patients With Early COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Coronavirus Disease 2019"
      ],
      "interventions": [
        {
          "name": "Pentarlandir™ UPPTA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SyneuRx International (Taiwan) Corp",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 90,
      "start_date": "2021-08-24",
      "completion_date": "2022-03",
      "has_results": false,
      "last_update_posted_date": "2021-12-17",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 12,
      "location_summary": "Cullman, Alabama • Gilbert, Arizona • Bradenton, Florida + 6 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04911777"
    },
    {
      "nct_id": "NCT04405739",
      "title": "The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV 2"
      ],
      "interventions": [
        {
          "name": "EIDD-2801",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ridgeback Biotherapeutics, LP",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2020-06-16",
      "completion_date": "2022-02-21",
      "has_results": true,
      "last_update_posted_date": "2023-03-23",
      "last_synced_at": "2026-07-22T18:47:12.173Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Oak Lawn, Illinois + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        },
        {
          "city": "Park Ridge",
          "state": "Illinois"
        },
        {
          "city": "Shreveport",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04405739"
    }
  ]
}